Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol valerate/dienogest - Bayer HealthCare Pharmaceutials

Drug Profile

Estradiol valerate/dienogest - Bayer HealthCare Pharmaceutials

Alternative Names: Climodien; Climodiène; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme

Latest Information Update: 18 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenapharm
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Oral contraceptives; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • No development reported Acne
  • Discontinued Pregnancy

Most Recent Events

  • 18 Feb 2019 No recent reports of development identified after preregistration for Acne (Treatment-resistant) in European Union (PO)
  • 27 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for estradiol valerate/dienogest for Acne (treatment-resistant) in European Union
  • 31 Dec 2016 Preregistration for Acne (Treatment-resistant) in European Union (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top